Beleaguered Valeant ups Salix sales force

A day before releasing fourth-quarter 2016 earnings, the struggling Canadian specialty phama said it has scaled up its sales force by nearly 40% for two of its best-selling GI drugs.

By Judy Packer-Tursman • Feb. 28, 2017

Industry Pulse: Who's spending on R&D?

As top-selling drugs age, biopharma continues to hunt for ever-elusive innovation. Here are eight charts explaining which pharmas need it most, and which are turning to internal R&D to capture it. 

By Ned Pagliarulo • Feb. 28, 2017

Explore the Trendline➔

Commercialization

New drugs for obesity and Alzheimer’s look set to become blockbusters, reshaping pharma marketing strategies just as many current top-sellers near looming patent cliffs.

By BioPharma Dive staff

J&J unpacks pricing decisions in new transparency report

The mega-pharma's subsidiary Janssen debuted a report aiming to break down the complexities related to drug pricing.

By Jacob Bell • Feb. 27, 2017

Why drug pricing seems so complicated

Experts say pharma companies need to get better at incorporating clinical value into pricing and communicating this value.

By Judy Packer-Tursman • Feb. 27, 2017

Pfizer, Celltrion pushing for interchangeability with Inflectra

Positive data could support a claim of interchangeability for the biosimilar of Remicade. 

By Jacob Bell • Feb. 22, 2017

PhRMA launches Go Boldly's first science dialogue

The industry trade group has launched a new marketing and outreach effort aimed at turning attention away from drug prices and toward progress in pharmaceutical science.

By Judy Packer-Tursman • Feb. 22, 2017

PhRMA distances itself from Marathon

The trade group broke its silence about the recent drug pricing controversy ignited by approval of PhRMA-member Marathon Pharmaceutical's DMD drug. 

By Lisa LaMotta • Feb. 16, 2017

PBM scrutiny grows under pushback against rising costs

New York State is taking steps against pharmacy benefits managers, but the PBMs don't think they are to blame.

By Suzanne Elvidge • Feb. 15, 2017

Generics trade group rebrands, emphasizing 'accessible' medicines

GPhA's transformation into the Association for Accessible Medicines focuses on families and budgets, a sharp contrast to PhRMA's new Go Boldly marketing push. 

By Judy Packer-Tursman • Feb. 15, 2017

Senators call on HHS' Price to fast track Canadian drug imports

Sens. Charles Grassley, Amy Klobuchar and John McCain are urging Trump's pick to consider an idea aimed at reducing the burden of high prescription drug costs.

By Jacob Bell • Feb. 14, 2017

Neurocrine enters licensing deal for Parkinson's drug

The company has agreed to pay Portuguese drugmaker Bial $30 million upfront for access to Ongentys, which gained approval in Europe last summer.

By Jacob Bell • Feb. 10, 2017

Regeneron, Sanofi win reprieve from court ban on Praluent

But the biotech's forecast for slower sales of its key drug Eylea in 2017 will give investors a new concern to think over. 

By Ned Pagliarulo • Feb. 9, 2017

FTC accuses Shire subsidiary of delaying generic rivals

According to a complaint filed Tuesday, Shire ViroPharma allegedly used "sham" citizen petitions to gum up FDA review of generic copies of its drug. 

By Judy Packer-Tursman • Feb. 8, 2017

Express Scripts says branded drug prices rose nearly 11% last year

The large PBM contrasted those rising costs with the slower cost growth experienced by its members, touting its efforts to secure rebates from drugmakers.

By Jacob Bell • Feb. 6, 2017

Kaleo faces political pressure over drug price hikes

Democratic Senator Amy Klobuchar asked Kaleo for an explanation why it increased the price of its opioid overdose treatment by more than 500% over three years. 

By Judy Packer-Tursman • Feb. 6, 2017

Novo Nordisk waffles due to US political uncertainty

The diabetes drugmaker is having trouble predicting future sales as a new administration in the U.S. begins setting policy goals for the industry. 

By Lisa LaMotta • Feb. 2, 2017

Merck unveils new Keytruda DTC ad

With Bristol-Myers' Opdivo faltering, Merck is hammering home Keytruda's competitive advantage in first-line lung cancer.

By Jacob Bell • Feb. 1, 2017

Biogen nixes licensing deal for autoimmune drug

The Cambridge biotech had paid Mitsubishi Tanabe $60 million to gain access to the drug a year and a half ago, but hopes for a Gilenya competitor didn't pan out. 

By Judy Packer-Tursman • Feb. 1, 2017

Pharma goes to Washington, Trump talks pricing

Pharmaceutical executives met with the new President and got the first sense of what the administration plans for the industry. 

By Lisa LaMotta • Jan. 31, 2017

Biogen expects slow ramp for Spinraza

The big biotech was upbeat about prospects for Spinraza, but admitted there will be obstacles to a successful launch.

By Lisa LaMotta • Jan. 26, 2017

Payers balk at price of EpiPen rival

Kaleo Pharma set the list price of Auvi-Q at $4,500 — higher than Mylan's EpiPen — even as it promises low costs for patients. 

By Jacob Bell • Jan. 25, 2017

PhRMA focuses on science, not pricing in new campaign

The industry lobbying group sidesteps hot button issues in its new ad campaign, focusing on biopharma's value and the "indomitable will' of its scientists.

By Judy Packer-Tursman • Jan. 25, 2017

FDA report stresses importance of Phase 3 testing

Several rumored candidates for FDA chief under President Trump have previously criticized the FDA approval process as being too slow. 

By Judy Packer-Tursman • Jan. 25, 2017

Anthem limits coverage for Biogen's new SMA drug

Despite Spinraza's broad label, Anthem restricted coverage to only those patients with the most severe forms of the genetic disease. 

By Ned Pagliarulo • Jan. 24, 2017

Shkreli bites back at industry ad campaign

Model of bad behavior or industry scapegoat?

By Lisa LaMotta • Jan. 24, 2017